This guide breaks down every question people are asking about microdosing, from the exact unit-by-unit chart to the weekly schedule most patients follow, the real science on inflammation, and the honest part most articles skip: when microdosing simply isnt enough, and what to do next
Key finding: AOD 9604 reduced visceral fat by 38%, improved HOMA-IR by 52%, and corrected glucose intolerance (fasting glucose -28%)
Our findings suggest that a randomised controlled trial of GLP-1 receptor agonist use in people with diabetes and depression, anxiety, or both would be worthwhile. Professor Mark Taylor from Griffith University, and one of the studys authors, said: An earlier study examining Swedish registers found the use of GLP-1 medications to be associated with a reduced risk of alcohol use disorder
Chemotherapy may be used in high-risk or metastatic cases
People will still have options, Conti added